What is Anhui Anke Biotechnology (Group) Co., Ltd.'s (300009.SZ) StockRank?

MoatMap's StockRank for Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) is 86/100, with a Strong Buy signal. This is a composite score combining Quality (83), Value (48), and Momentum (43) factor ranks across MoatMap's 19,000+ stock universe.

Does Anhui Anke Biotechnology (Group) Co., Ltd. have an economic moat?

Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Anhui Anke Biotechnology (Group) Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Anhui Anke Biotechnology (Group) Co., Ltd. in?

Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300009.SZ

STRONG BUYREMOVE

Anhui Anke Biotechnology (Group) Co., Ltd. · Healthcare · China · $2.1B · Avg Vol: $18M/d

StockRank

P/E (TTM)

18.6x

ROE

15.4%

D/E

0.0x

Dividend %

3.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Anhui Anke Biotechnology develops biopharmaceuticals. While it is a quality business, it is not a pure-play CDMO and does not benefit from the specific CDMO pricing power cycle theme, as it focuses on proprietary drug commercialization in China.

COMPANY DESCRIPTION

Anhui Anke Biotechnology (Group) Co., Ltd. develops, manufactures, and markets biopharmaceutical products, with a core focus on recombinant human growth hormone (r-hGH) and interferon. The company is a major player in China's pediatric endocrinology and oncology supportive care markets, benefiting from high technical barriers and strong brand trust among clinicians. Its continuous R&D in monoclonal antibodies and cell therapies supports long-term growth.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	345M	424M	375M	391M	4.3%
EPS	0.06	0.08	0.06	0.07	0.8%
Shares	1.7B	1.7B	1.7B	1.7B	-0.0%
Debt	5M	8M	8M	5M	-0.2%
Equity	474M	552M	610M	674M	12.4%
Op CF	103M	141M	101M	128M	7.3%
Inv CF	-80M	-91M	-25M	-67M	—
Fin CF	-23M	-59M	-70M	-69M	—

PRICE (1M)-11.4%

SMA 50SMA 200

$1.16

RSI (14)

44.8

52W High

$1.87

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

17.0%88.5

ROE

15.4%83.7

GP/Assets

34.6%72.5

Op. Margin

35.3%95.3

FCF/Assets

7.9%81.2

Piotroski

—83.5

Int. Cover

50.0x91.4

D/E Ratio

0.01x91.6

Current Ratio

4.30x66.0

Value

P/E (TTM)

18.6x61.1

EV/EBITDA

13.5x31.4

P/FCF

215.7x39.1

P/B

2.8x43.6

P/S

5.1x40.6

Div Yield

3.2%73.9

Momentum

52W High %

62%43.3

RS 6M

-24%49.1

SMA 50/200

0.90x34.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—62.4

Q Growth

-20%24.6

FUNDAMENTALS

Market Cap

$2.1B

P/E (Forward)

11.0x

Gross Margin

74.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300009.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300009.SZ	Anhui Anke Biotechnology (Group) Co., Ltd.(you)	$2.1B	86	STRONG BUY
6821.HK	Asymchem Laboratories (Tianjin) Co., Ltd.	$4.2B	88	STRONG BUY
2142.HK	HBM Holdings Limited	$1.2B	94	STRONG BUY
002007.SZ	Hualan Biological Engineering Inc.	$3.7B	78	BUY
688526.SS	Wuhan Keqian Biology Co.,Ltd	$906M	83	STRONG BUY
000990.SZ	Chengzhi Co., Ltd.	$1.7B	63	HOLD
688336.SS	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd	$5.9B	80	BUY
688046.SS	GemPharmatech Co., Ltd.	$1.2B	70	BUY
301047.SZ	Sino Biological,Inc.	$1.1B	70	BUY
002287.SZ	Tibet Cheezheng Tibetan Medicine Co., Ltd.	$1.8B	60	HOLD

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) — Stock Score Summary

Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) has a MoatMap StockRank of 86/100 based on Quality (83/100), Value (48/100), and Momentum (43/100) factor scores. The current signal is STRONG BUY. Anhui Anke Biotechnology develops biopharmaceuticals. While it is a quality business, it is not a pure-play CDMO and does not benefit from the specific CDMO pricing power cycle theme, as it focuses on proprietary drug commercialization in China.

Key Financial Metrics

Price	$1.16
Market Cap	$2.1B
P/E (TTM)	18.62
P/E (Forward)	11.01
Price/Book	2.76
Return on Equity	15.4%
Return on Invested Capital	17.0%
Debt/Equity	0.62
Gross Margin	74.7%
Operating Margin	35.3%
Revenue Growth	-13.8%
Dividend Yield	3.2%
Free Cash Flow	$10M

Anhui Anke Biotechnology (Group) Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Anhui Anke Biotechnology (Group) Co., Ltd.’s (300009.SZ) StockRank?: MoatMap’s StockRank for Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) is 86/100, with a Strong Buy signal. It is a composite of Quality (83), Value (48), and Momentum (43) factor ranks across MoatMap’s 19,000+ stock universe.
Does Anhui Anke Biotechnology (Group) Co., Ltd. have an economic moat?: Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Anhui Anke Biotechnology (Group) Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) is Strong Buy, based on a StockRank of 86/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Anhui Anke Biotechnology (Group) Co., Ltd. in?: Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).